Product Images Procort

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 3 images provide visual information about the product associated with Procort NDC 50967-357 by Womens Choice Pharmaceuticals Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

procortPI2

procortPI2

The text provides information for the patient on the use of topical corticosteroids, including instructions on dosage and administration, what to avoid, and the possible adverse reactions. It also warns about the potential risks of using topical corticosteroids during pregnancy and nursing, and mentions the greater susceptibility of pediatric patients to adverse reactions. The text also discusses laboratory tests that may be helpful in evaluating the suppression of the hypothalamic-pituitary-adrenal (HPA) axis caused by topical corticosteroids. The medication supplied is Hydrocortisone Acetate 1.85%, Pramoxine HCl 115% topical cream.*

procort PI

procort PI

ProCont® is a topical preparation containing Hydrocortisone Acetate and Pramoxine Hydrochloride, which are anti-inflammatory, anti-pruritic, and vasoconstrictive agents. Pramoxine Hydrochloride is a topical anesthetic agent that provides temporary relief from itching and pain. Topical corticosteroids are absorbed through the skin, and once absorbed, they can be handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. However, topical corticosteroids are contraindicated in patients with a history of hypersensitivity to any of the components of the preparation. Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Therefore, patients receiving a large dose of a potent topical steroid, applied to a large surface area and under an occlusive dressing, should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug or to reduce the frequency of application or to substitute a less potent steroid. Recovery of the HPA axis function is generally prompt and complete upon discontinuation of the drug.*

updated2018

updated2018

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.